The results of Kikushige Y et al., who found that injection of TIM-3+ AML cells in immune-deficient mice could establish an AML model and subsequent TIM-3 blockers could alleviate disease, supported the efficacy of this targeted approach (8). Here, HAVCR2 is linked to acute myeloid leukemia.